Is polycystic ovary syndrome associated with elevated muscle sympathetic nerve activity?
blood pressure
cardiovascular health
muscle sympathetic nerve activity
polycystic ovary syndrome
sympathoexcitation
Journal
Experimental physiology
ISSN: 1469-445X
Titre abrégé: Exp Physiol
Pays: England
ID NLM: 9002940
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
31
03
2023
accepted:
14
08
2023
pubmed:
29
8
2023
medline:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
Polycystic ovary syndrome (PCOS) is a complex disorder characterized by reproductive abnormalities, cardiometabolic disturbances and a heightened risk of cardiovascular disease. A small but compelling body of research demonstrates that females with PCOS present with elevated muscle sympathetic nerve activity (MSNA) at rest. Heightened MSNA is present in lean, overweight and obese females with PCOS, but limited evidence suggests that androgens may be more strongly linked to elevated MSNA in lean females with PCOS than in obese females with PCOS. Although the specific mechanisms underlying elevated MSNA in PCOS remain elusive, sympathetic activation is implicated in the progression of several cardiovascular diseases and may contribute to the cardiovascular pathophysiology of PCOS. Encouragingly, MSNA appears responsive to non-pharmacological intervention, making the sympathetic nervous system a promising therapeutic target to mitigate cardiovascular risk in PCOS. This brief review summarizes the existing evidence regarding elevated MSNA, cardiovascular risk profile and vascular function, as well as the potential for clinical intervention and future research directions in females with PCOS. NEW FINDINGS: What is the topic of this review? The presence of elevated muscle sympathetic nerve activity in females with polycystic ovary syndrome and the implications for cardiovascular health. What advance does it highlight? The sympathetic nervous system likely contributes to elevated cardiovascular disease risk in females with polycystic ovary syndrome. Moreover, it presents as a promising therapeutic target for mitigating cardiovascular disease and merits further investigation.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250-1256Subventions
Organisme : Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC)
ID : RGPIN-2018-05961
Organisme : FRQ | Fonds de Recherche du Québec - Santé (FRQS)
ID : 268920
Informations de copyright
© 2023 The Authors. Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.
Références
Amiri, M., Ramezani Tehrani, F., Behboudi-Gandevani, S., Bidhendi-Yarandi, R., & Carmina, E. (2020). Risk of hypertension in women with polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Reproductive Biology and Endocrinology, 18(1), 23.
Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. Clinical Endocrinology, 95(4), 531-541. Scopus.
Berbrier, D. E., Leone, C. A., Adler, T. E., Bender, J. R., Taylor, H. S., Stachenfeld, N. S., & Usselman, C. W. (2023). Effects of androgen excess and body mass index on endothelial function in women with polycystic ovary syndrome. Journal of Applied Physiology, 134(4), 868-878.
Burnstock, G. (2009). Autonomic neurotransmission: 60 years since sir Henry Dale. Annual Review of Pharmacology and Toxicology, 49(1), 1-30.
Carmassi, F., Negri, F. D., Fioriti, R., Giorgi, A. D., Giannarelli, C., Fruzzetti, F., Pedrinelli, R., Dell'Omo, G., & Bersi, C. (2005). Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thrombosis Research, 116(3), 207-214.
Carmina, E. (2022). Need to introduce the finding of obesity or normal body weight in the current diagnostic criteria and in the classification of PCOS. Diagnostics, 12(10), 2555.
Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016). Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction, 31(11), 2619-2631.
Castellano, C.-A., Baillargeon, J.-P., Nugent, S., Tremblay, S., Fortier, M., Imbeault, H., Duval, J., & Cunnane, S. C. (2015). Regional brain glucose hypometabolism in young women with polycystic ovary syndrome: Possible link to mild insulin resistance. PLoS ONE, 10(12), e0144116.
Cecelja, M., & Chowienczyk, P. (2012). Role of arterial stiffness in cardiovascular disease. JRSM Cardiovascular Disease, 1(4), 1.
Charkoudian, N., & Rabbitts, J. A. (2009). Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clinic Proceedings, 84(9), 822-830.
del Campo, M., Lagos, N., & Lara, H. (2020). In vivo blockade of ovarian sympathetic activity by Neosaxitoxin prevents polycystic ovary in rats. Journal of Endocrinology, 244(3), 523-533.
De Melo, V. U., Saldanha, R. R. M., Dos Santos, C. R., De Campos Cruz, J., Lira, V. A., Santana-Filho, V. J., & Michelini, L. C (2016). Ovarian hormone deprivation reduces oxytocin expression in paraventricular nucleus preautonomic neurons and correlates with baroreflex impairment in rats. Frontiers in Physiology, 7, 461.
Dunaif, A., & Fauser, B. C. J. M. (2013). Renaming PCOS-a two-state solution. The Journal of Clinical Endocrinology and Metabolism, 98(11), 4325-4328.
Ely, B. R., Francisco, M. A., Halliwill, J. R., Bryan, S. D., Comrada, L. N., Larson, E. A., Brunt, V. E., & Minson, C. T. (2019). Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in women who are obese with polycystic ovary syndrome. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 317(5), R630-R640.
Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270-284.
Espinoza, J. A., Alvarado, W., Venegas, B., Domínguez, R., & Morales-Ledesma, L. (2018). Pharmacological sympathetic denervation prevents the development of polycystic ovarian syndrome in rats injected with estradiol valerate. Reproductive Biology and Endocrinology, 16(1), 86.
Forslund, M., Schmidt, J., Brännström, M., Landin-Wilhelmsen, K., & Dahlgren, E. (2022). Morbidity and mortality in PCOS: A prospective follow-up up to a mean age above 80 years. European Journal of Obstetrics and Gynecology and Reproductive Biology, 271, 195-203.
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 7(4), 219-231.
Grassi, G., Dell'Oro, R., Facchini, A., Quarti Trevano, F., Bolla, G. B., & Mancia, G. (2004). Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. Journal of Hypertension, 22(12), 2363-2369.
Gui, J., & Wang, R. (2017). Cardiovascular autonomic dysfunction in women with polycystic ovary syndrome: A systematic review and meta-analysis. Reproductive BioMedicine Online, 35(1), 113-120.
Hansen, S. L., Bojsen-Møller, K. N., Lundsgaard, A.-M., Hendrich, F. L., Nilas, L., Sjøberg, K. A., Hingst, J. R., Serup, A. K., Olguín, C. H., Carl, C. S., Wernblad, L. F., Henneberg, M., Lustrup, K. M., Hansen, C., Jensen, T. E., Madsbad, S., Wojtaszewski, J. F. P., Richter, E. A., & Kiens, B. (2020). Mechanisms underlying absent training-induced improvement in insulin action in lean, hyperandrogenic women with polycystic ovary syndrome. Diabetes, 69(11), 2267-2280.
Hetemäki, N., Mikkola, T. S., Tikkanen, M. J., Wang, F., Hämäläinen, E., Turpeinen, U., Haanpää, M., Vihma, V., & Savolainen-Peltonen, H. (2021). Adipose tissue estrogen production and metabolism in premenopausal women. The Journal of Steroid Biochemistry and Molecular Biology, 209, 105849.
Kalil, G. Z., & Haynes, W. G. (2012). Sympathetic nervous system in obesity-related hypertension: Mechanisms and clinical implications. Hypertension Research, 35(1), 4.
Ketel, I. J., Stehouwer, C. D., Henry, R. M., Serné, E. H., Hompes, P., Homburg, R., Smulders, Y. M., & Lambalk, C. B. (2010). Greater arterial stiffness in polycystic ovary syndrome (PCOS) is an obesity- but not a PCOS-associated phenomenon. The Journal of Clinical Endocrinology & Metabolism, 95(10), 4566-4575.
Lambert, E. A., Teede, H., Sari, C. I., Jona, E., Shorakae, S., Woodington, K., Hemmes, R., Eikelis, N., Straznicky, N. E., De Courten, B., Dixon, J. B., Schlaich, M. P., & Lambert, G. W. (2015). Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. Clinical Endocrinology, 83(6), 812-819.
Landsberg, L. (2001). Insulin-mediated sympathetic stimulation: Role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). Journal of Hypertension, 19(Supplement), 523.
Lansdown, A., & Rees, D. A. (2012). The sympathetic nervous system in polycystic ovary syndrome: A novel therapeutic target? Clinical Endocrinology, 77(6), 791-801.
Lansdown, A. J., Warnert, E. A. H., Sverrisdóttir, Y., Wise, R. G., & Rees, D. A. (2019). Regional cerebral activation accompanies sympathoexcitation in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 104(9), 3614-3623.
Lauritsen, M. P., Bentzen, J. G., Pinborg, A., Loft, A., Forman, J. L., Thuesen, L. L., Cohen, A., Hougaard, D. M., & Nyboe Andersen, A. (2014). The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Human Reproduction, 29(4), 791-801.
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013). Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 98(12), 4565-4592.
Macefield, V. G., & Henderson, L. A. (2019). Identification of the human sympathetic connectome involved in blood pressure regulation. Neuroimage, 202, 116119.
Malpas, S. C. (2010). Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiological Reviews, 90(2), 513-557.
Nardone, M., Floras, J. S., & Millar, P. J. (2020). Sympathetic neural modulation of arterial stiffness in humans. American Journal of Physiology. Heart and Circulatory Physiology, 319(6), H1338-H1346.
Paradisi, G., Steinberg, H. O., Hempfling, A., Cronin, J., Hook, G., Shepard, M. K., & Baron, A. D. (2001). Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 103(10), 1410-1415.
Park, J., Middlekauff, H. R., & Campese, V. M. (2012). Abnormal sympathetic reactivity to the cold pressor test in overweight humans. American Journal of Hypertension, 25(12), 1236-1241.
Pernow, J., Schwieler, J., Kahan, T., Hjemdahl, P., Oberle, J., Wallin, B. G., & Lundberg, J. M. (1989). Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. American Journal of Physiology. Heart and Circulatory Physiology, 257(3), H866-H872.
Philbois, S. V., Gastaldi, A. C., de Paula Facioli, T., Felix, A. C. S., Dos Reis, R. M., Fares, T. H., & de Souza, H. C. D. (2019). Women with polycystic ovarian syndrome exhibit reduced baroreflex sensitivity that may be associated with increased body fat. Arquivos Brasileiros de Cardiologia, 112(4), 424-429.
Reckelhoff, J. F., Shawky, N. M., Romero, D. G., & Yanes Cardozo, L. L. (2022). Polycystic ovary syndrome: Insights from preclinical research. Kidney360, 3(8), 1449-1457.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19(1), 41-47.
Schlaich, M. P., Straznicky, N., Grima, M., Ika-Sari, C., Dawood, T., Mahfoud, F., Lambert, E., Chopra, R., Socratous, F., Hennebry, S., Eikelis, N., Böhm, M., Krum, H., Lambert, G., Esler, M. D., & Sobotka, P. A. (2011). Renal denervation: A potential new treatment modality for polycystic ovary syndrome? Journal of Hypertension, 29(5), 991-996.
Shoemaker, J. K., Klassen, S. A., Badrov, M. B., & Fadel, P. J. (2018). Fifty years of microneurography: Learning the language of the peripheral sympathetic nervous system in humans. Journal of Neurophysiology, 119(5), 1731-1744.
Shorakae, S., Ranasinha, S., Abell, S., Lambert, G., Lambert, E., de Courten, B., & Teede, H. (2018). Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clinical Endocrinology, 89(5), 628-633.
Skrapari, I., Tentolouris, N., & Katsilambros, N. (2006). Baroreflex function: Determinants in healthy subjects and disturbances in diabetes, obesity and metabolic syndrome. Current Diabetes Reviews, 2(3), 329-338.
Sprung, V. S., Atkinson, G., Cuthbertson, D. J., Pugh, C. J. A., Aziz, N., Green, D. J., Cable, N. T., & Jones, H. (2013). Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: A meta-analysis of the observational studies. Clinical Endocrinology, 78(3), 438-446.
Stener-Victorin, E., Jedel, E., Janson, P. O., & Sverrisdottir, Y. B. (2009). Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 297(2), R387-R395.
Sverrisdóttir, Y. B., Mogren, T., Kataoka, J., Janson, P. O., & Stener-Victorin, E. (2008). Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? American Journal of Physiology. Endocrinology and Metabolism, 294(3), E576-E581.
Trakakis, E., Balanika, A., Baltas, C., Loghis, C., Simeonidis, G., Vaggopoulos, V., Papakonstantinou, O., Gouliamos, A., Salamalekis, G., & Kassanos, D. (2008). Hemodynamic alterations and wall properties in large arteries of young, normotensive, and non-obese women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 31(11), 1001-1007.
Usselman, C. W., Coovadia, Y., & Adler, T. E. (2019). Sympathetic reactivity in lean individuals with polycystic ovary syndrome. Proceedings of the Canadian Society for Exercise Physiology 52nd Annual General Meeting /Actes Du 52e Congrès Annuel de La Société Canadienne de Physiologie de l'exercice, 44, S55-S120.
Vogel, B., Acevedo, M., Appelman, Y., Bairey Merz, C. N., Chieffo, A., Figtree, G. A., Guerrero, M., Kunadian, V., Lam, C. S. P., Maas, A. H. E. M., Mihailidou, A. S., Olszanecka, A., Poole, J. E., Saldarriaga, C., Saw, J., Zühlke, L., & Mehran, R. (2021). The lancet women and cardiovascular disease commission: Reducing the global burden by 2030. The Lancet, 397(10292), 2385-2438.
Young, C. N., Deo, S. H., Chaudhary, K., Thyfault, J. P., & Fadel, P. J. (2010). Insulin enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in humans. The Journal of Physiology, 588(18), 3593-3603.
Zhang, J., Xu, J.-H., Qu, Q.-Q., & Zhong, G.-Q. (2020). Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: A meta-analysis of cohort studies. Frontiers in Cardiovascular Medicine, 7, 552421.